miR‐145 is a potential biomarker for predicting clinical outcome in glioblastomas

Abstract

miR‐145 has been found to be significantly downregulated in gliomas, and overexpression of miR‐145 increases glioma cell apoptosis and enhances chemosensitivity or herpes simplex virus thymidine kinase gene therapy. However, the correlation between miR‐145 and the clinical prognosis of glioblastomas has never been explored. In this study, a retrospective study was conducted in 86 cases of patients with glioblastoma after neurosurgery combined with chemoradiotherapy, and 36 cases with traumatic brain injury. Our results showed that miR‐145 was significantly lower in glioblastoma tissues than that in normal brain tissue (P < 0.05). Furthermore, miR‐145 was lower in patients with lower Karnofsky Performance Scale (KPS) scores than in patients with higher KPS scores ( P < 0.05). Cox Regression analysis showed that low miR‐145 expression was associated with poor patient survival ( P < 0.05). These data suggested that patients with glioblastoma with lower miR‐145 expression are prone to shorter overall survival.

MicroRNA‐145 suppresses cell migration and invasion in upper tract urothelial carcinoma by targeting ARF6

“…Some studies have reported that lower expression of miR‐145‐5p could predict poor prognosis in different cancer patients. For example, low expression of miR‐145‐5p has been associated with poor prognosis in prostate cancer, gastric cancer, cervical cancer, glioblastomas, and NSCLC . These studies suggest that the downregulation of miR‐145‐5p might predict disease‐free survival or cancer‐specific survival of UTUC patients.…”

“…n = 4. Results were shown as mean ± SD; *P < .05 and **P < .01 cancer, 47,48 gastric cancer, 49 cervical cancer, 50 glioblastomas, 51 and NSCLC. 52 These studies suggest that the downregulation of miR-145-5p might predict disease-free survival or cancer-specific survival of UTUC patients.…”

ADAM17 Confers Temozolomide Resistance in Human Glioblastoma Cells and miR-145 Regulates Its Expression

“…In particular, several studies have indicated that miR-145 could inhibit epithelial-to-mesenchymal transition [41], migration, and invasion [23] and increase the cytotoxicity of drug treatment in GBM [42,43]. Furthermore, the potential of miR-145 as a biomarker for predicting clinical outcomes of patients with GBM has been demonstrated [44,45]. In addition, other miRNAs that regulate ADAM17 expression have been explored.…”